Form 4: Ovid Therapeutics Director Acquires RSUs

Ovid Therapeutics Inc. reports that Director Kevin Joseph Fitzgerald was granted restricted stock units (RSUs) as part of his compensation.

Summary

• Kevin Joseph Fitzgerald, a Director at Ovid Therapeutics Inc., received an award of 17,578 restricted stock units (RSUs) on April 7, 2026.
• This RSU award is in lieu of an annual cash retainer for his board service, valued at $45,000.
• The RSUs vest in tranches: 25% upon grant, and the remaining 75% vesting in equal installments on June 30, 2026, September 30, 2026, and December 31, 2026.
• Vesting is contingent upon Fitzgerald's continued service to the company through each respective vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on standard director compensation through equity awards and does not contain performance-related financial information or strategic updates.

Positives

• Director compensation is being structured through equity awards, aligning director interests with shareholders.
• The RSU award structure provides for staggered vesting, encouraging continued service and commitment to the company.

Negatives

• The filing does not indicate any negative financial performance or operational issues.

Risks

• The value of the RSUs is subject to the future performance of Ovid Therapeutics Inc.'s stock price.
• Continued service is a condition for vesting, meaning any departure from the board before vesting dates would result in forfeiture of unvested RSUs.

Future Outlook

The filing primarily details a compensation award and does not contain forward-looking financial guidance or strategic outlook statements.

Industry Context

StockSavvy.ai notes that the use of Restricted Stock Units (RSUs) for director compensation is a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive and director incentives with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The RSU award aligns director incentives with shareholder interests, as the value of the award is tied to the company's stock performance.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation structure for its board members.
• Directors: Kevin Joseph Fitzgerald receives equity compensation for his services, with vesting contingent on continued service.

Next Steps

• Continued service by Kevin Joseph Fitzgerald through the specified vesting dates (June 30, 2026, September 30, 2026, and December 31, 2026) to receive full vesting of RSUs.

Key Dates

Keywords

Ovid Therapeutics, OVID, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, RSU Award, Insider Transaction, Equity Compensation